SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.” 

SV’s Houman Ashrafian said the firm had been looking to create a cell therapy startup with “a truly off-the-shelf approach that is manufacturable at a reasonable cost and can be delivered to patients efficiently in the last mile,” is efficacious in solid tumors, and is able to overcome the immunosuppressive tumor microenvironment. ...